The perspects and challenges of immunotherapy for lung cancer

潘莹莹; 周彩存

doi:10.19401/j.cnki.1007-3639.2019.04.001

您当前的位置：

首页 >

文章列表页 >

The perspects and challenges of immunotherapy for lung cancer

更新时间：2026-01-27

- The perspects and challenges of immunotherapy for lung cancer
- China Oncology Vol. 29, Issue 4, Pages: 241-249(2019)
- 作者机构：
  
  同济大学附属上海市肺科医院肿瘤科,上海,200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.04.001
  CLC： R734.2
- Published Online：17 May 2019，
  
  Published：17 May 2019
- 稿件说明：
移动端阅览
潘莹莹，周斐，周彩存. 肺癌免疫治疗的前景与挑战[J]. 中国癌症杂志, 2019, 29(4): 241-249.

潘莹莹, 周彩存. The perspects and challenges of immunotherapy for lung cancer[J]. China Oncology, 2019, 29(4): 241-249.
潘莹莹，周斐，周彩存. 肺癌免疫治疗的前景与挑战[J]. 中国癌症杂志, 2019, 29(4): 241-249. DOI： 10.19401/j.cnki.1007-3639.2019.04.001.

潘莹莹, 周彩存. The perspects and challenges of immunotherapy for lung cancer[J]. China Oncology, 2019, 29(4): 241-249. DOI： 10.19401/j.cnki.1007-3639.2019.04.001.

摘要

近年来，肺癌的治疗发生了翻天覆地的变化，针对免疫检查点的免疫治疗显著改善了晚期肺癌患者的生存。多项随机对照研究证实，在二线治疗中，与标准化疗相比免疫治疗可显著延长患者的总生存期，因此免疫治疗目前已成为晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的标准二线治疗。近期一些研究还奠定了免疫治疗联合化疗在一线治疗中的地位。然而，免疫治疗总有效率方法不高，目前尚缺乏精准的疗效预测分子标志物，本文对目前肺癌免疫治疗的进展以及未来的发展方向进行了综述。

Abstract

In recent years

the treatment of lung cancer has undergone earth-shaking changes. The application for immunotherapy targeting immune checkpoint has significantly improved the survival outcomes of advanced lung cancer patients. Several randomized-controlled trials have shown that immunotherapy significantly improves the overall survival of advanced non-small cell lung cancer (NSCLC) patients when compared with standard chemotherapy in second-line setting. Therefore

immunotherapy is the standard second-line therapy currently. Several clinical trials have also demonstrated the role of immunotherapy in combination with chemotherapy in first-line setting. However

it should be noted that the overall response rate of immunotherapy is not high enough

and it currently lacks of accurately predictive biomarkers for immunotherapy. This article summarizes the current progress of immunotherapy for lung cancer and also provides insights into future directions.

关键词

Keywords

references

Views

4350

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Anti-tumor activities of CIK cells derived from lymph nodes of lung cancer patients

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanism study of MYC promoting proliferation and metastasis in prostate cancer by targeting CD47

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Research status and progress of third-line treatment for metastatic colorectal cancer

Related Author

滕家俊

周　严

刘显勋

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

Related Institution

上海市胸科医院呼吸内科

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology

Department of Urology, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology

AI问答

⁰